What one share of Travere Therapeutics holds
We are a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Our approach centers on advancing our innovative pipeline with multiple late-stage clinical programs targeting rare diseases with significant unmet medical needs.
Travere Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $6.48 |
|---|---|
| Profit | −$0.48 |
| Cash and investments | $1.25 |
| Book value | $0.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2011 | $0.00 | −$0.22 | — | — | — | −$0.56 |
| 2012 | $0.00 | −$0.14 | — | — | — | −$0.59 |
| 2012 | — | −$8.29 | $0.01 | −$0.75 | — | — |
| 2013 | $0.00 | −$2.44 | $0.01 | −$1.25 | — | −$1.07 |
| 2014 | $1.13 | −$4.43 | $0.03 | −$1.86 | — | −$1.43 |
| 2015 | $2.66 | $3.12 | $0.00 | −$0.04 | — | $8.23 |
| 2016 | $3.49 | −$1.29 | $0.04 | −$0.13 | — | $8.12 |
| 2017 | $4.00 | −$1.54 | $0.02 | $0.17 | — | $7.44 |
| 2018 | $4.06 | −$2.54 | $0.02 | −$0.64 | — | $7.69 |
| 2019 | $4.14 | −$3.46 | $0.00 | −$1.38 | — | $5.13 |
| 2020 | $4.17 | −$3.56 | $0.14 | −$1.04 | — | $4.04 |
| 2021 | $2.20 | −$3.01 | $0.09 | −$0.33 | — | $4.83 |
| 2022 | $1.72 | −$4.37 | $0.00 | −$2.92 | — | $0.67 |
| 2023 | $1.96 | −$1.50 | $0.01 | −$3.78 | — | $2.66 |
| 2024 | $2.96 | −$4.08 | — | — | — | $0.68 |
| 2025 | $5.50 | −$0.29 | — | — | — | $1.26 |
Common questions about Travere Therapeutics
How much does one share of Travere Therapeutics earn?
Over the last 12 months, Travere Therapeutics lost $0.48 for each share on $6.48 of sales.
Does Travere Therapeutics pay a dividend?
Travere Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Travere Therapeutics’s book value per share?
Travere Therapeutics’s book value is $0.26 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Travere Therapeutics have?
Each share of Travere Therapeutics has $1.25 of cash and investments, as of June 30, 2026.
Has Travere Therapeutics bought back shares?
Travere Therapeutics’s share count rose about 83525% from 2011 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.